Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
Die nächste Sicherheitsgeneration: Quantenresistente Technologie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
IB

WKN: A42J54 | ISIN: US46062X4025 | Ticker: PF4
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
INTERPACE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
INTERPACE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur INTERPACE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoInterpace Biosciences GAAP EPS of -$0.26, revenue of $10.4M1
MoInterpace Biosciences, Inc.: Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results1
INTERPACE BIOSCIENCES Aktie jetzt für 0€ handeln
05.11.INTERPACE BIOSCIENCES, INC. - 8-A12B, Registration of securities-
30.10.INTERPACE BIOSCIENCES, INC. - S-1/A, General form for registration of securities2
15.10.INTERPACE BIOSCIENCES, INC. - 8-K, Current Report1
15.10.Interpace Biosciences, Inc.: Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue1
25.09.INTERPACE BIOSCIENCES, INC. - S-1, General form for registration of securities-
17.09.INTERPACE BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans2
26.08.Interpace Biosciences announces 1-for-5 reverse stock split1
26.08.Interpace Biosciences, Inc.: Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting207PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) ("Interpace" or the "Company"), an emerging leader in enabling personalized medicine, today announced that...
► Artikel lesen
21.08.INTERPACE BIOSCIENCES, INC. - 8-K, Current Report-
10.08.INTERPACE BIOSCIENCES, INC. - 10-Q, Quarterly Report1
10.08.Interpace Biosciences, Inc.: Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results217Q2 Revenue of $9.1 millionQ2 Income from Continuing Operations of $0.3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid...
► Artikel lesen
12.05.Interpace Biosciences, Inc.: Interpace Biosciences Announces First Quarter 2026 Financial and Business Results285Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May...
► Artikel lesen
30.03.Interpace Biosciences, Inc.: Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results491Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4...
► Artikel lesen
03.12.25Interpace Biosciences, Inc.: Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners270PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) ("Interpace" or the "Company") today announced that it has fully repaid its outstanding term loan facility...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1